EntreMed Inc. (Nasdaq: ENMD) is a pharmaceutical company focused on the development of therapeutic pharmaceutical candidates to treat cancer and inflammation. To reach its goals, the company must maintain an experienced and aggressive management team. EntreMed today announced Thomas H. Bliss will serve as the company’s senior vice president of corporate and business development.
“It has long been our goal to advance the development of our promising clinical pipeline and to partner those product candidates in order to enhance their value and expedite their progress through the regulatory approval process. Partnering, particularly for ENMD-2076, is a principal goal of the company in 2008. We welcome Tom to EntreMed’s senior management team to help us accomplish this milestone. I am confident that Tom’s extensive knowledge and experience will better position us to aggressively seek partnership opportunities,” James S. Burns, EntreMed’s president and CEO stated in the press release.
Bliss was appointed by the company’s board of directors, in part due to his previous management roles. Bliss has more than 20 years biotechnology business development and healthcare investment banking experience. He previously served as international licensing, licensing operations oversight and the coordination and communication of Amgen’s China/India Research Activities Initiative at Amgen; was responsible for directing all Amgen acquisition activity, including the acquisition of Abgenix; served as vice president of biopharmaceuticals business development at Baxter BioScience; and served in many more roles, including analytical support and investment banking.
“I chose to join EntreMed at this exciting juncture in its development because it allows me to be an integral part of the build-out of what I believe will become a leading biotechnology company. With three oncology products already in the clinic and a rheumatoid arthritis product entering the clinic, the company’s clinical pipeline is ripe for a multitude of partnering and business development opportunities,” stated Bliss. “In addition, EntreMed’s core research and development competency will continue to provide new compounds for potential business development initiatives. I am delighted to lead these efforts and look forward to supporting the company’s growth strategy for developing drugs for oncology and inflammatory diseases.”
Let us hear your thoughts below:
